Rational design of HIV vaccine and microbicides: Report of the EUROPRISE annual conference

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Wahren, Britta ^a   Biswas, Priscilla ^b   Borggren, Marie ^c   Coleman, Adam ^d   Da Costa, Kelly ^e   De Haes, Winni ^f   Dieltjens, Tessa ^f   Dispinseri, Stefania ^b,g   Grupping, Katrijn ^f   Hallengärd, David ^a   Hornig, Julia ^d   Klein, Katja ^e   Mainetti, Lara ^b,h   Palma, Paolo ⁱ   Reudelsterz, Marc ^j   Seifried, Janna ^j   Selhorst, Philippe ^f   Sköld, Annette ^a   van Gils, Marit J ^l   Weber, Caroline ^k   Shattock, Robin ^e   Scarlatti, Gabriella ^b   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c LUND UNIVERSITY   (Sweden)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^g UNIVERSITY OF MILAN   (Italy)

^h VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

ⁱ UNIVERSITY OF ROME TOR VERGATA   (Italy)

^j ROBERT KOCH INSTITUTE   (Germany)

^k INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^l ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CARBOMER; CHITOSAN; DAPIVIRINE; DENDRITIC CELL VACCINE; DNA VACCINE; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; LENTIVIRUS VECTOR; LIVE VACCINE; MICROBICIDE; NANOPARTICLE; OLIPIPHAT; PLACEBO; POLYLACTIC ACID; PRO 2000; RECOMBINANT GROWTH HORMONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS ANTIGEN; ZIDOVUDINE; ANTIINFECTIVE AGENT;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; CELL POPULATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION SENSITIVITY; NONHUMAN; REVIEW; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANIMAL; CONFERENCE PAPER; DISEASE PREDISPOSITION; EUROPE; IMMUNOLOGY; MOUSE; MUCOSAL IMMUNITY; SERODIAGNOSIS; SYNTHESIS; ERRATUM; ERROR;

ADAPTIVE IMMUNITY; AIDS VACCINES; ANIMALS; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE SUSCEPTIBILITY; DRUG DESIGN; EUROPE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; MICE; NEUTRALIZATION TESTS;

EID: 77954884081     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-72     Document Type: Review

References (48)

1. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM. "MIATA"-minimal information about T cell assays. Immunity 2009, 31:527-528. 10.1016/j.immuni.2009.09.007, 19833080.
2. Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 2009, 4:e4505. 10.1371/journal.pone.0004505, 2640999, 19229336.
3. Scarlatti G, Alcami J, Bongertz V, Fenyö EM, Heath A, Heyndrickx L, Holmes H, Jansson M, Lopalco L, Malnati M, et al. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group. Retrovirology 2009, 6(Suppl 3):P46.
4. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M. Prognostic value of HIV-1 syncytiuminducing phenotype for rate of CD4 + cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681-688.
5. Vicenzi E, Bordignon PP, Biswas P, Brambilla A, Bovolenta C, Cota M, Sinigaglia F, Poli G. Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation. J Virol 1999, 73:7515-7523. 104278, 10438841.
6. Sato A, Iwasaki A. Peyer's patch dendritic cells as regulators of mucosal adaptive immunity. Cell Mol Life Sci 2005, 62:1333-1338. 10.1007/s00018-005-5037-z, 15971108.
7. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001, 14:430-445. 10.1128/CMR.14.2.430-445.2001, 88982, 11292646.
8. Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol 2006, 6:859-868. 10.1038/nri1960, 1796806, 17063186.
9. Schmitt D, Dezutter-Dambuyant C. Epidermal and mucosal dendritic cells and HIV1 infection. Pathol Res Pract 1994, 190:955-959.
10. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin AM, Moog C. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006, 80:6177-6181. 10.1128/JVI.02625-05, 1472578, 16731957.
11. Klinman DM, Tross D, Klaschik S, Shirota H, Sato T. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Ann N Y Acad Sci 2009, 1175:80-88. 10.1111/j.1749-6632.2009.04970.x, 19796080.
12. Ciabattini A, Pettini E, Arsenijevic S, Pozzi G, Medaglini D. Intranasal immunization with vaccine vector Streptococcus gordonii elicits primed CD4 + and CD8 + T cells in the genital and intestinal tracts. Vaccine 2010, 28:1226-1233. 10.1016/j.vaccine.2009.11.021, 19945415.
13. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol 2006, 80:5283-5291. 10.1128/JVI.02013-05, 1472142, 16699008.
14. Lindqvist M, Persson J, Thorn K, Harandi AM. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 2009, 182:6435-6443. 10.4049/jimmunol.0900136, 19414797.
15. Lindqvist M, Navabi N, Jansson M, Samuelson E, Sjoling A, Orndal C, Harandi AM. Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice. Vaccine 2009, 28:270-278. 10.1016/j.vaccine.2009.09.083, 19800444.
16. Effros RB, Allsopp R, Chiu CP, Hausner MA, Hirji K, Wang L, Harley CB, Villeponteau B, West MD, Giorgi JV. Shortened telomeres in the expanded CD28-CD8 + cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. Aids 1996, 10:F17-22. 10.1097/00002030-199607000-00001, 8828735.
17. Effros RB. Impact of the Hayflick Limit on T cell responses to infection: lessons from aging and HIV disease. Mech Ageing Dev 2004, 125:103-106. 10.1016/j.mad.2003.11.003, 15037010.
18. Rethi B, Fluur C, Atlas A, Krzyzowska M, Mowafi F, Grutzmeier S, De Milito A, Bellocco R, Falk KI, Rajnavolgyi E, Chiodi F. Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. Aids 2005, 19:2077-2086. 10.1097/01.aids.0000189848.75699.0f, 16284456.
19. Zipeto D, Matucci A, Ripamonti C, Scarlatti G, Rossolillo P, Turci M, Sartoris S, Tridente G, Bertazzoni U. Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes. Microbes Infect 2006, 8:1424-1433. 10.1016/j.micinf.2006.03.001, 16702010.
20. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H. Cross-Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression. J Infect Dis 2010, 201:1045-53. 10.1086/651144, 20170371.
21. Dieltjens T, Heyndrickx L, Willems B, Gray E, Van Nieuwenhove L, Grupping K, Vanham G, Janssens W. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10- like antibodies. Retrovirology 2009, 6:113. 10.1186/1742-4690-6-113, 2801487, 20003438.
22. Mainetti L, Mullins J, Scarlatti G. Humoral immune response in acute HIV-1 infection. Retrovirology 2009, 6(Suppl 3):P48.
23. Bunnik EM, Euler Z, Welkers M, Grijsen M, Prins J, Schuitemaker H. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level. Retrovirology 2009, 6(Suppl 3):P389.
24. Barabas S, Gary R, Bauer T, Lindner J, Lindner P, Weinberger B, Jilg W, Wolf H, Deml L. Urea-mediated cross-presentation of soluble Epstein-Barr virus BZLF1 protein. PLoS Pathog 2008, 4:e1000198. 10.1371/journal.ppat.1000198, 2572144, 18989461.
25. Isgro A, Leti W, De Santis W, Marziali M, Esposito A, Fimiani C, Luzi G, Pinti M, Cossarizza A, Aiuti F, Mezzaroma I. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4 + T cell counts despite viral suppression during HAART. Clin Infect Dis 2008, 46:1902-1910. 10.1086/588480, 18462177.
26. Dardenne M, Smaniotto S, de Mello-Coelho V, Villa-Verde DM, Savino W. Growth hormone modulates migration of developing T cells. Ann N Y Acad Sci 2009, 1153:1-5. 10.1111/j.1749-6632.2008.03977.x, 19236321.
27. Tesselaar K, Miedema F. Growth hormone resurrects adult human thymus during HIV-1 infection. J Clin Invest 2008, 118:844-847. 2248805, 18292816.
28. Darzy KH, Shalet SM. Pathophysiology of radiation-induced growth hormone deficiency: efficacy and safety of GH replacement. Growth Horm IGF Res 2006, 16(Suppl A):S30-40. 10.1016/j.ghir.2006.03.002, 16624606.
29. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220. 10.1056/NEJMoa0908492, 19843557.
30. Das AT, Klaver B, Centlivre M, Harwig A, Ooms M, Page M, Almond N, Yuan F, Piatak M, Lifson JD, Berkhout B. Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution. Retrovirology 2008, 5:44. 2443169, 18533993.
31. Falkensammer B, Rubner B, Hiltgartner A, Wilflingseder D, Stahl Hennig C, Kuate S, Uberla K, Norley S, Strasak A, Racz P, Stoiber H. Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replicationdeficient viral vectors. Retrovirology 2009, 6:60. 10.1186/1742-4690-6-60, 2713197, 19545395.
32. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008, 5:e157. discussion e157, 10.1371/journal.pmed.0050157, 2494562,2494562, 18684007.
33. Cranage MP, Fraser CA, Stevens Z, Huting J, Chang M, Jeffs SA, Seaman MS, Cope A, Cole T, Shattock RJ. Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol 2010, 3:57-68. 10.1038/mi.2009.110, 19741600.
34. Michelini Z, Negri DR, Baroncelli S, Spada M, Leone P, Bona R, Klotman ME, Cara A. Development and use of SIV-based Integrase defective lentiviral vector for immunization. Vaccine 2009, 27:4622-4629. 10.1016/j.vaccine.2009.05.070, 2754741, 19523909.
35. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D, Llactic- co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 2004, 22:2406-2412. 10.1016/j.vaccine.2003.12.032, 15193402.
36. Aline F, Brand D, Pierre J, Roingeard P, Severine M, Verrier B, Dimier-Poisson I. Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 2009, 27:5284-5291. 10.1016/j.vaccine.2009.05.028, 19450633.
37. Buonaguro L, Devito C, Tornesello ML, Schroder U, Wahren B, Hinkula J, Buonaguro FM. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007, 25:5968-5977. 10.1016/j.vaccine.2007.05.052, 17629365.
38. Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM. Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles. J Virol 2009, 83:304-313. 10.1128/JVI.01606-08, 2612330, 18945779.
39. Lori F, Trocio J, Bakare N, Kelly LM, Lisziewicz J. DermaVir, a novel HIV immunisation technology. Vaccine 2005, 23:2030-2034. 10.1016/j.vaccine.2005.01.004, 15755566.
40. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Reverse transcriptase inhibitors as potential colorectal microbicides. Agents Chemother 2009, 53:1797-1807.
41. Stax MJ, van Montfort T, Sprenger RR, Melchers M, Sanders RW, van Leeuwen E, Repping S, Pollakis G, Speijer D, Paxton WA. Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes. Virology 2009, 391:203-211. 10.1016/j.virol.2009.06.011, 19682628.
42. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448. 10.1038/363446a0, 8502296.
43. Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A, Kelly C, McKnight A, et al. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)- neutralizing properties and high affinity for HIV-1 gp120. J Virol 2008, 82:12069-12081. 10.1128/JVI.01379-08, 2593325, 18842738.
44. Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006, 6:371-382. 10.1038/nri1848, 16639430.
45. Martinez J, Coplan P, Wainberg MA. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?. Antiviral Res 2006, 71:343-350. 10.1016/j.antiviral.2006.05.013, 16787667.
46. Clarke C, Smyth MJ. Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol 2007, 25:192-193. 10.1038/nbt0207-192, 17287754.
47. Spetz AL, Patterson BK, Lore K, Andersson J, Holmgren L. Functional gene transfer of HIV DNA by an HIV receptor-independent mechanism. J Immunol 1999, 163:736-742.
48. Ochieng W, Sauermann U, Schulte R, Suh YS, Kim KS, Sung YC, Hunsmann G, Stahl-Hennig C, Sopper S. Susceptibility to Simian immunodeficiency virus ex vivo predicts outcome of a prime-boost vaccine after SIVmac239 challenge. J Acquir Immune Defic Syndr 2009, 52:162-169. 10.1097/QAI.0b013e3181b22f4a, 19644382.